Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism
Identifieur interne : 006139 ( Main/Exploration ); précédent : 006138; suivant : 006140Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism
Auteurs : Kurlan [États-Unis] ; Michael H. Kim [États-Unis] ; Don M. Gash [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1991.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Administration, Oral, Animals, Antiparkinson Agents, Carbidopa (administration & dosage), Carbidopa (toxicity), Disease Models, Animal, Dose-Response Relationship, Drug, Drug Combinations, Levodopa, Levodopa (administration & dosage), Levodopa (toxicity), MPTP, Macaca mulatta, Neurologic Examination (methods), Neurologic Examination (veterinary), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinsonism, Rating scale, Rhesus monkeys, Stereotyped Behavior (drug effects).
- MESH :
- chemical , administration & dosage : Carbidopa, Levodopa.
- chemical , toxicity : Carbidopa, Levodopa.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Antiparkinson Agents, Drug Combinations.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Stereotyped Behavior.
- drug therapy : Parkinson Disease, Secondary.
- methods : Neurologic Examination.
- veterinary : Neurologic Examination.
- Administration, Oral, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Macaca mulatta.
Abstract
Quantitative measures for the severity of MPTP‐induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose‐response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose‐response relationship for levodopa over the dosage range of 50–3, 500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000–2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP‐induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.
Url:
DOI: 10.1002/mds.870060205
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002918
- to stream Istex, to step Curation: 002918
- to stream Istex, to step Checkpoint: 004282
- to stream PubMed, to step Corpus: 004D92
- to stream PubMed, to step Curation: 004D92
- to stream PubMed, to step Checkpoint: 004E05
- to stream Ncbi, to step Merge: 002C11
- to stream Ncbi, to step Curation: 002C11
- to stream Ncbi, to step Checkpoint: 002C11
- to stream Main, to step Merge: 009443
- to stream Main, to step Curation: 006139
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism</title><author><name sortKey="Kurlan" sort="Kurlan" uniqKey="Kurlan" last="Kurlan">Kurlan</name></author><author><name sortKey="Kim, Michael H" sort="Kim, Michael H" uniqKey="Kim M" first="Michael H." last="Kim">Michael H. Kim</name></author><author><name sortKey="Gash, Don M" sort="Gash, Don M" uniqKey="Gash D" first="Don M." last="Gash">Don M. Gash</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:07F4BED8D2D9465BA0C6F2B5BCCFAEFA9D1B1EE6</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1002/mds.870060205</idno><idno type="url">https://api.istex.fr/document/07F4BED8D2D9465BA0C6F2B5BCCFAEFA9D1B1EE6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002918</idno><idno type="wicri:Area/Istex/Curation">002918</idno><idno type="wicri:Area/Istex/Checkpoint">004282</idno><idno type="wicri:doubleKey">0885-3185:1991:Kurlan:oral:levodopa:dose</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2057003</idno><idno type="wicri:Area/PubMed/Corpus">004D92</idno><idno type="wicri:Area/PubMed/Curation">004D92</idno><idno type="wicri:Area/PubMed/Checkpoint">004E05</idno><idno type="wicri:Area/Ncbi/Merge">002C11</idno><idno type="wicri:Area/Ncbi/Curation">002C11</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C11</idno><idno type="wicri:doubleKey">0885-3185:1991:Kurlan R:oral:levodopa:dose</idno><idno type="wicri:Area/Main/Merge">009443</idno><idno type="wicri:Area/Main/Curation">006139</idno><idno type="wicri:Area/Main/Exploration">006139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism</title><author><name sortKey="Kurlan" sort="Kurlan" uniqKey="Kurlan" last="Kurlan">Kurlan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kim, Michael H" sort="Kim, Michael H" uniqKey="Kim M" first="Michael H." last="Kim">Michael H. Kim</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gash, Don M" sort="Gash, Don M" uniqKey="Gash D" first="Don M." last="Gash">Don M. Gash</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurobiology and Anatomy, University of Rochester School of Medicine, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1991">1991</date><biblScope unit="vol">6</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="111">111</biblScope><biblScope unit="page" to="118">118</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">07F4BED8D2D9465BA0C6F2B5BCCFAEFA9D1B1EE6</idno><idno type="DOI">10.1002/mds.870060205</idno><idno type="ArticleID">MDS870060205</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Administration, Oral</term><term>Animals</term><term>Antiparkinson Agents</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (toxicity)</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Combinations</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (toxicity)</term><term>MPTP</term><term>Macaca mulatta</term><term>Neurologic Examination (methods)</term><term>Neurologic Examination (veterinary)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Parkinsonism</term><term>Rating scale</term><term>Rhesus monkeys</term><term>Stereotyped Behavior (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Antiparkinson Agents</term><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Stereotyped Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Macaca mulatta</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Quantitative measures for the severity of MPTP‐induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose‐response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose‐response relationship for levodopa over the dosage range of 50–3, 500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000–2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP‐induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Kurlan" sort="Kurlan" uniqKey="Kurlan" last="Kurlan">Kurlan</name></region><name sortKey="Gash, Don M" sort="Gash, Don M" uniqKey="Gash D" first="Don M." last="Gash">Don M. Gash</name><name sortKey="Kim, Michael H" sort="Kim, Michael H" uniqKey="Kim M" first="Michael H." last="Kim">Michael H. Kim</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:07F4BED8D2D9465BA0C6F2B5BCCFAEFA9D1B1EE6
|texte= Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |